Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA.

Area of Science:

• Oncology
• Genomics
• Biomarker Discovery

Background:

• Early cancer detection improves patient outcomes and reduces treatment morbidity.
• Circulating cell-free DNA (cfDNA) analysis offers a minimally invasive approach for cancer detection.
• Targeted methylation patterns in cfDNA hold promise for identifying multiple cancer types.

Purpose of the Study:

• To assess the performance of targeted cfDNA methylation analysis for detecting and localizing multiple cancer types.
• To evaluate the specificity and sensitivity of the assay across different cancer stages.
• To determine the accuracy of tissue of origin (TOO) prediction using cfDNA methylation data.

Main Methods:

• A prospective case-control study involving 6689 participants (2482 cancer, 4207 non-cancer).
• Plasma cfDNA bisulfite sequencing targeting over 100,000 informative methylation regions.
• Development and validation of a classifier for cancer detection and TOO localization.

Main Results:

• High specificity (99.3%) with a low false-positive rate (0.7%) in the validation set.
• Sensitivity for Stages I-III cancers was 67.3% in 12 key cancer types and 43.9% overall.
• Detection sensitivity increased with cancer stage, reaching 92% for Stage IV in key types.
• Tissue of origin was accurately predicted in 93% of samples with a cancer signal.

Conclusions:

• Targeted cfDNA methylation analysis effectively detects over 50 cancer types across various stages.
• The assay demonstrates high specificity and accuracy in predicting the tissue of origin.
• Further prospective population-level studies are warranted to evaluate this promising early detection test.